Evommune, Inc. (EVMN) SEC Filings https://ir.evommune.com/financial-information/sec-filings/rss Evommune, Inc. (EVMN) - SEC Filings en-us https://d1io3yog0oux5.cloudfront.net/_2094dba4d31887f5c3cda4773c265127/evommune/files/theme/images/logo-sm.png Evommune, Inc. Logo Equisolve Investor Relations Suite <![CDATA[424B3 - Prospectus [Rule 424(b)(3)]]]> https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-212038/0001193125-26-212038.pdf Thu, 07 May 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-212038/0001193125-26-212038.pdf <![CDATA[10-Q - Quarterly report [Sections 13 or 15(d)]]]> https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-211963/0001193125-26-211963.pdf Thu, 07 May 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-211963/0001193125-26-211963.pdf <![CDATA[8-K - Current report]]> https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-211934/0001193125-26-211934.pdf Thu, 07 May 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-211934/0001193125-26-211934.pdf <![CDATA[EFFECT - Notice of Effectiveness]]> https://ir.evommune.com/financial-information/sec-filings/content/9999999995-26-001330/9999999995-26-001330.pdf Mon, 27 Apr 26 00:15:17 -0400 https://ir.evommune.com/financial-information/sec-filings/content/9999999995-26-001330/9999999995-26-001330.pdf <![CDATA[424B3 - Prospectus [Rule 424(b)(3)]]]> https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-177356/0001193125-26-177356.pdf Fri, 24 Apr 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-177356/0001193125-26-177356.pdf <![CDATA[ARS - Annual Report to Security Holders]]> https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-166761/0001193125-26-166761.pdf Tue, 21 Apr 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-166761/0001193125-26-166761.pdf <![CDATA[DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material]]> https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-166755/0001193125-26-166755.pdf Tue, 21 Apr 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-166755/0001193125-26-166755.pdf <![CDATA[DEF 14A - Definitive proxy statements]]> https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-166747/0001193125-26-166747.pdf Tue, 21 Apr 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-166747/0001193125-26-166747.pdf <![CDATA[4 - Statement of changes in beneficial ownership of securities]]> https://ir.evommune.com/financial-information/sec-filings/content/0002092017-26-000003/0002092017-26-000003.pdf Fri, 17 Apr 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0002092017-26-000003/0002092017-26-000003.pdf <![CDATA[4 - Statement of changes in beneficial ownership of securities]]> https://ir.evommune.com/financial-information/sec-filings/content/0002091053-26-000003/0002091053-26-000003.pdf Fri, 17 Apr 26 00:00:00 -0400 https://ir.evommune.com/financial-information/sec-filings/content/0002091053-26-000003/0002091053-26-000003.pdf